Boehringer Ingelheim, breakthrough therapies and innovative healthcare solutions developer, completed the acquisition of Labor Dr. Merk & Kollegen, R&D and clinical manufacturing performer with a focus on Advanced Therapy Medicinal Products-based cancer immunology treatments. Financial terms were not disclosed. "The acquisition of Labor Dr. Merk & Kollegen strengthens our promising oncology pipeline with a focus on immuno-oncology and tumor cell-oriented active ingredients. We have many potential first-in-class therapies for cancers for which there are no satisfactory therapy options so far," Dr. Michel Pairet, Boehringer Ingelheim Member of the Management.